Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

Vagus Nerve Stimulation in Refractory Epilepsy

FDA-Approved Indication

  • Vagus nerve stimulation (VNS) is FDA-approved and indicated as adjunctive therapy for patients with refractory epilepsy who have failed to control their seizures with antiepileptic medications alone, with FDA approval received in 1997 specifically for refractory epilepsy as an adjunctive therapy, typically after patients have failed two or more anti-epileptic drugs 1, 2

Expected Efficacy Outcomes

  • Approximately 51% of patients experience a 50% or greater reduction in seizure frequency with VNS, according to the American Academy of Neurology 1, 3

Clinical Evidence Base

  • The efficacy of VNS was established through rigorous multicenter randomized controlled trials (E03 and E05 trials), which demonstrated that high-intensity stimulation parameters were significantly more efficacious than low-intensity stimulation, with a mean 30.9% seizure frequency reduction compared to 11.3% with low VNS (p = 0.029) 1, 3

Mechanisms of Action

  • VNS works through both preventive and acute seizure termination mechanisms, including continuous intermittent stimulation, closed-loop stimulation triggered by ictal tachycardia, and on-demand stimulation via handheld magnet, as recommended by the American Epilepsy Society 1, 4, 5

Important Clinical Considerations

  • For non-responders to initial settings, increasing the duty cycle can significantly improve outcomes, with responder rates increasing from 19% to 35% (p = 0.046), as suggested by the American Academy of Neurology 4, 5